Clinical trial
Decitabine in Treating Patients With Myelodysplastic Syndrome
NCT00003361 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003361 |
|---|---|
| Title | Decitabine in Treating Patients With Myelodysplastic Syndrome |
| Official title | Phase II Study With Decitabine (5-aza-2'-Deoxycytidine, DAC) in Myelodysplastic Syndromes |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | decitabine |
| Enrollment | 75 |
| Start date | Apr 1, 1998 |
| Primary completion | Sep 1, 2003 |
| Completion | Dec 1, 2009 |
| First posted | Mar 12, 2004 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: